AmeboGenesis Unveils Sustainable Amebocyte Production For LAL Testing, Saving Horseshoe Crabs

AmeboGenesis™ has recently announced a significant breakthrough in the field of biotechnology with the development of a sustainable method for producing Amebocytes, which are crucial for Limulus Amebocyte Lysate (LAL) production used in medical endotoxin testing. This new technology eliminates the need to harvest blood from horseshoe crabs, a practice that has raised concerns over the potential endangerment of the species. Traditionally, around 800,000 horseshoe crabs are harvested annually for their blood, which is a key component in ensuring the safety of injectable drugs, vaccines, and implantable devices globally.

The proprietary technology developed by AmeboGenesis offers an unlimited production capacity for bio-identical Amebocytes, maintaining the high standards required for LAL testing while significantly reducing environmental impact. The innovative method involves harvesting leg muscles from horseshoe crabs, which are then cultured and differentiated into Amebocytes using totipotent stem cells. This process not only ensures a consistent concentration and production of LAL but also allows for precise control over Amebocyte production in a laboratory setting. The result is an improvement in test reliability, accuracy, and robustness.

This pioneering approach by AmeboGenesis marks the first instance worldwide where expansion and differentiation of amebocyte precursors in cell cultures have been achieved. The cultured cells exhibit identical genetic, morphological, biochemical, and functional characteristics to their native counterparts and have been validated to respond to endotoxins effectively, meeting the industry's gold standard for efficacy.

A leader in biotechnology innovation, AmeboGenesis, LLC is committed to impacting the biomedical, pharmaceutical, and food safety sectors positively. Their dedication to sustainable and reproducible Amebocyte production establishes new standards for medical testing, product safety, and environmental conservation. A subsidiary of MygoGenesis, LLC, AmeboGenesis is also at the forefront of transforming the creation of Autologous Totipotent Cells from Somatic Cells through their innovative Mygotic Process™. This platform is designed to erase all epigenetics without altering the DNA for use across various applications including cell therapies, gene therapies, and regenerative medicine.

For more information on AmeboGenesis and its transformative technology, interested parties are encouraged to visit their official website at www.amebogenesis.com.